Radiation therapy (with associated chemotherapy) is the standard treatment for nasopharyngeal carcinoma. Conformal intensity-modulated radiation therapy is a new and particularly interesting technique for these tumors, due to their complex volumes close to many critical organs. Better dosimetric results and improved protection of adjacent healthy tissue have been shown compared with conventional 2D or 3D radiation therapy, with significantly reduced side-effects, notably xerostomia. Excellent local control rates have been reported.
Introduction
Nasopharyngeal carcinoma, especially when of the undifferentiated type, differs from other head and neck cancers geographically and ethnically and by its association with Epstein-Barr virus and specific treatment requirements. Treatment is hindered by the anatomic proximity of numerous critical organs, restricting indications for surgery to biopsy for initial histologic diagnosis and to cases of relapse. Radiation therapy (RT) is the keystone of local treatment [1] .
In locally advanced cancer, the overall survival benefit of associating radiation therapy and chemotherapy was demonstrated in Baujat et al.'s meta-analysis, especially when the association was concomitant [2] .
The efficacy of adjuvant chemotherapy is under assessment, certain retrospective reports suggesting an impact on tumor control [3] .
Progress in imaging (magnetic resonance imaging (MRI) and positron emission tomography coupled to computed tomography (PET-CT)) has improved initial extension assessment in nasopharyngeal carcinoma [4] , enhancing the precision of RT planning.
More recently, conformal intensity-modulated radiation therapy (IMRT) has become standard clinical practice.
IMRT uses multiple small radiation beams of varying intensities and shapes thanks to a multileaf collimator.
This optimizes tumor area coverage while protecting healthy neighboring organs.
The present study successively examines the various radiation target volumes and healthy organs to be spared (organs at-risk: OARs) and the fractionation and dose options. We shall also review the data demonstrating the specific benefit of IMRT over 2D and 3D strategies. Finally, we shall report results for local control, and look at foreseeable future developments.
Definition of target volumes
RT planning requires target volumes to be defined on a CT-scan for dosimetry. This is performed in dorsal decubitus, with a 5-point thermoformed contention mask (immobilization of head, neck and shoulders), without and, if possible, with intravenous iodized contrast injection, and thin (3 mm) slice acquisition from vertex to superior mediastinum. The target volumes to be defined are as follows [5] .
GTV
Gross tumor volume (GTV) is the tumor mass visible on clinical examination, endoscopy and imaging. It includes the nasopharyngeal tumor (tumoral GTV) and involved lymph nodes (nodal GTV). GTV after neoadjuvant chemotherapy includes not only the residual volume but the whole initial tumor and involved lymph nodes. Delineation is improved by fusion of the planning CT scan and the initial MRI. However attractive the option may seem, fusion with PET-CT is not recommended in routine practice, for lack of validation in the literature. 
CTV
Clinical target volume (CTV) includes GTV plus any immediately neighboring microscopic tumor or lymph-node extensions, taking account of the natural extension pathways of nasopharyngeal carcinoma. CTV thus includes:
• above: the inferior part of the sphenoid sinus, and the middle cranial fossa, including foramina (ovale and lacerum); • below, the oropharyngeal mucosa;
• laterally, the parapharyngeal spaces;
• anteriorly, the posterior part of the nasal cavities and the pterygomaxillary fossa; • posteriorly, the retropharyngeal space and clivus [1, 6, 7] (Figs. 1 and 2).
Some authors also include the cavernous sinus (superiorly), pterygoid muscles and carotid space (laterally) and the posterior third of the maxillary sinuses (anteriorly) in the CTV [7] [8] [9] . Nasopharyngeal carcinoma being highly lymphophilic, nodal CTV systematically includes bilateral levels II to V (Robbins classification) and the bilateral retropharyngeal lymph-node areas [10, 11] .
PTV
Planning target volume (PTV) is delineated geometrically by drawing a 3-5 mm margin around the tumoral or lymph-node CTV, to allow for uncertainty related to patient positioning and systematic or variable internal movement.
Organs at risk (OARs)
Healthy organs are also delineated, to ensure protection: brainstem, brain (temporal lobe and posterior fossa), spinal cord, optic chiasm, cochlea, optic nerves, lens, parotid glands, submandibular glands, mandible, temporomandibular joints, pharyngeal constrictor muscles, larynx, esophagus, and thyroid and pituitary glands.
IMRT dose prescription
IMRT uses 5 to 7 radiation beams, with fluence adjusted from fraction to fraction. Planning is inverse: i.e., dose ranges to be delivered to the PTV and OARs are determined initially by the physician, and dosimetry seeks to remain within these predefined limits. IMRT enables a tailored dose to be delivered within the volume to be treated, several CTVs and thus several distinct PTVs being defined. Dose per PTV is determined according to risk of invasion (Fig. 3 ) [12] .
There are a number of IMRT techniques: SIB (Simultaneous Integrated Boost), SMART (Simultaneous Modulated Accelerated Radiation Therapy), or sequential (partially conformal 3D RT and partially IMRT). In SIB the highest dose per fraction is delivered to the highest-risk PTV, which usually includes the GTV, with lower doses to medium or low-risk PTVs. High-risk PTV dose per fraction is around 2 Gy/day. SMART combines integrated boost and accelerated radiation with a smaller number of fractions; high-risk PTV dose per fraction is thus greater than 2.2 Gy/day, and often around 2.3 Gy/fraction [12] . Table 1 shows examples of dose levels and fractionation in nasopharyngeal carcinoma IMRT [13] [14] [15] [16] .
Dose escalation
Retrospective studies of nasopharyngeal carcinoma indicate a tumoricidal dose of ≥ 70 Gy. Dose escalation has been described in nasopharyngeal carcinoma, by brachytherapy or conformal or stereotaxic radiation, but with increased late toxicity [17, 18] . IMRT appears to be a promising means of increasing PTV doses while sparing OARs. Kwong et al., however, in a series of 50 patients with T3-T4 nasopharyngeal lesions treated by concomitant chemotherapy and RT with IMRT up to 76 Gy by 2.17 Gy fractions, reported 96% locoregional control at 25 months' follow-up but increased late toxicity, with 4% of patients showing temporal necrosis and 4% severe epistaxis [19] .
Late toxicities are mainly due to the increased dose per fraction. Special attention should therefore be paid to the risk of late OAR toxicities in case of dose per fraction exceeding 2 Gy.
Thanks to the cellular hypoxia marker 18F-fluoromisonidazole, PET-CT may in future improve the targeting of dose escalation. This marker could indicate hypoxic and radioresistant tumor areas, defining an HTV (hypoxic tumor volume). A dosimetric study in 8 patients by Choi et al. reported a dose escalation in the HTV up to 78 Gy (by 2.6 Gy fractions) to be feasible in 75% of cases [20] . The clinical benefit of this attitude remains to be proven.
Benefit of IMRT

Local control
Dosimetric studies demonstrated benefit for IMRT over conformal RT in nasopharyngeal carcinoma, with improved dose homogeneity and PTV coverage [21, 22] .
Peng et al. [23] , in a prospective study, recently reported that IMRT provided significantly better 5-year locoregional control than 2D RT (90% vs 85%, P = 0.04). However, no phase-III randomized trials have as yet compared IMRT versus 3D conformal RT. Several teams have published results, but retrospectively; the RTOG 0225 study is a non-randomized phase-II trial [13, 14, 16, [24] [25] [26] [27] [28] [29] [30] [31] (cf. Table 2) .
Even so, all series showed excellent control, exceeding 90%.
Protection of healthy organs
In nasopharyngeal carcinoma, radiation therapy may induce late complications due to partial irradiation of neighboring healthy organs, also increased which concomitant chemotherapy: xerostomia, dysphagia, dental problems, neurologic disorders (temporal lobe necrosis, cranial nerve damage, impaired cognitive function, hearing loss), cervical fibrosis, carotid stenosis, or endocrine disorders due to involvement of the thyroid gland or hypothalamicpituitary axis.
Tuan et al. [32] , in a large cohort of 796 patients treated by exclusive 2D RT at 66-70 Gy, recently reported high rates of late toxicities, with 73% of patients showing at least one complication and, especially, a 46% rate of xerostomia (grade not specified).
Kam et al. [22] reported that IMRT significantly reduced mean and maximum OAR doses compared to 2D or 3D RT. Clinical benefit of such reduced OAR irradiation was reported by Peng et al., with significantly fewer long-term side-effects (neurologic, salivary, muscular and cutaneous toxicity) (P < 0.05), while Ma et al. reported improved quality of life at more than 2 years' follow-up [23, 33] . Three randomized studies compared IMRT versus 2D RT [23, 34, 35] and one prospective non-randomized study compared IMRT versus 3D RT [36] . On varying criteria (common toxicity criteria, salivary flow, quality of life), all four found significantly lower rates of xerostomia with IMRT (Table 3 ) [37] .
In the future, OAR sparing may be further enhanced by dynamic arc therapy, enabling circular irradiation with continuous adaptation of multileaf collimator positioning according to target and OAR volumes. Initial dosimetric studies reported excellent conformation to target volumes, with improvement over conventional IMRT and reduced radiation time [38] .
Adaptive radiation therapy
In nasopharyngeal carcinoma, IMRT uses steep dose gradients in dosimetric planning, especially for OARs such as the spinal cord and brainstem. This requires strict quality control before and during therapy, notably including daily control of patient positioning.
Over 6-7 weeks' treatment, anatomic changes may nevertheless appear, due to weight-loss, tumor response or salivary gland hypotrophy, modifying the initially planned dosimetry with a risk of increased OAR irradiation and poorer tumor volume cover.
Several authors have recommended a systematic second planning CT scan performed halfway through treatment, around the 25th fraction [39] . The clinical benefit of this attitude remains to be proven, and it cannot yet be recommended in routine practice [40] .
Conclusion
In recent years, IMRT has become the standard attitude in nasopharyngeal carcinoma. It optimizes target volume cover and allows significantly less irradiation of healthy organs than conventional 2D or 3D RT. This leads to a lower rate of late toxicities, notably xerostomia. Benefit with respect to 3D RT in terms of locoregional control and survival, however, has yet to be demonstrated in randomized trials, although all data published to date reported excellent rates of local control: > 90% at 3 years.
Improved locoregional control and survival in nasopharyngeal carcinoma may be achieved by dose escalation targeted by metabolic imaging (18-fluoromisonidazole (F-MISO) PET), or associated targeted therapies (bevacizumab, cetuximab) to avoid metastatic failure.
Late toxicity may be also reduced by arc therapy, enhancing OAR sparing.
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